ORLANDO — Implantation of the iDose TR in combination with cataract surgery yielded robust IOP reduction while maintaining a positive safety profile, according to an analysis presented at the American Academy of Ophthalmology meeting.
The 12-month study included 60 patients with age-related cataract and open-angle glaucoma who were implanted with the iDose TR (travoprost intracameral implant, 75 mcg) during cataract surgery.
“At 1 year out, we found significant efficacy,” I. Paul Singh, MD, of the Eye Centers of Racine & Kenosha, told Healio.
{{VIDEO}}
The average IOP before treatment was